Nephrology · Metabolic stone clinic · KIMS Secunderabad
Renal Tubular Acidosis — When the Kidney Cannot Regulate Acid-Base Balance
Renal tubular acidosis (RTA) is a group of disorders in which the kidney's tubular system fails to properly acidify the urine — despite normal or near-normal glomerular filtration rate. In normal physiology, the kidney plays a critical role in maintaining blood pH by excreting hydrogen ions (acid) into the urine and regenerating bicarbonate (a base) to buffer the body's continuously generated metabolic acid load. In RTA, this process fails — acid accumulates in the blood (metabolic acidosis), bicarbonate is lost in the urine, and the downstream consequences include kidney stones, bone disease, growth retardation in children, and — in severe cases — life-threatening electrolyte abnormalities.
RTA is clinically important not as a common condition but as a frequently missed one. Many patients with RTA are investigated for recurrent kidney stones, unexplained bone disease, or metabolic acidosis without the underlying tubular defect being identified. At KIMS, the metabolic stone clinic specifically investigates Type 1 (distal) RTA in patients with recurrent calcium phosphate and mixed stones — a highly treatable cause of stone recurrence that is missed if the urine pH and serum bicarbonate are not measured.
Understanding the three types of RTA
The three RTA types differ in which part of the tubule fails, the resulting potassium abnormality, the urine pH pattern, and the clinical syndromes they produce.
Type 1 RTA — distal RTA (most clinically important for stone disease)
In Type 1 (distal) RTA, the collecting duct's intercalated cells — the cells responsible for secreting hydrogen ions into the final urine — are defective. The distal tubule cannot acidify the urine below a pH of 5.3 to 5.5 (normal minimum urine pH is below 5.0). The consequences of this failure: Metabolic acidosis — hydrogen ions that cannot be excreted in the urine accumulate in the blood, causing a normal anion gap metabolic acidosis with low serum bicarbonate. Hypokalaemia — the failure to secrete H+ is compensated by increased K+ excretion in the collecting duct, causing potassium wasting. Severe hypokalaemia can cause muscle weakness, paralysis, and cardiac arrhythmias. Hypercalciuria and hypocitruria — the chronically acidotic state mobilises calcium from bone and increases urinary calcium excretion. Simultaneously, citrate — the most important natural inhibitor of calcium stone formation — is reabsorbed in the proximal tubule in exchange for bicarbonate, reducing urinary citrate to very low levels. Calcium phosphate and mixed stones — the combination of hypercalciuria, hypocitruria, and alkaline urine (urine pH above 5.5 — calcium phosphate precipitates in alkaline urine far more readily than in acidic urine) creates ideal conditions for calcium phosphate stone formation. Type 1 RTA is the metabolic diagnosis in a substantial proportion of patients with recurrent calcium phosphate stones, bilateral stones, nephrocalcinosis, and stones beginning in childhood. Nephrocalcinosis — diffuse calcium deposition in the kidney parenchyma from hypercalciuria and alkaline urine. A characteristic radiological finding strongly associated with Type 1 RTA. Rickets and osteomalacia — chronic acidosis mobilises skeletal calcium and causes metabolic bone disease. Causes of Type 1 RTA. Primary (genetic — autosomal dominant or recessive mutations in proton pump subunits) · Autoimmune (Sjögren's syndrome — the most common cause of acquired distal RTA in adults; systemic lupus erythematosus) · Drugs (amphotericin B, lithium, ifosfamide) · Nephrocalcinosis (secondary RTA from calcium deposition damaging the distal tubule) · Sickle cell nephropathy.
Type 2 RTA — proximal RTA
In Type 2 (proximal) RTA, the proximal tubule — which reabsorbs approximately 85% of the filtered bicarbonate — is defective. Bicarbonate is lost in the urine (bicarbonaturea) until the serum bicarbonate falls low enough that the proximal tubule's reduced capacity is sufficient to reabsorb what remains. The result: a stable but low serum bicarbonate (typically 14 to 18 mEq/L), with urine pH that can be normal or low when serum bicarbonate is low (because the distal tubule is intact and can still acidify urine). Type 2 RTA causes metabolic acidosis with hypokalaemia and glycosuria, aminoaciduria, phosphaturia, and uricosuria — the full Fanconi syndrome when multiple proximal tubular functions are impaired. Causes of Type 2 RTA. Inherited (cystinosis — the most important cause in children; Wilson's disease; hereditary fructose intolerance; Lowe syndrome) · Multiple myeloma (light chain damage to the proximal tubule) · Drugs (tenofovir in HIV patients — causes proximal tubular toxicity including Type 2 RTA; ifosfamide; expired tetracycline) · Amyloidosis.
Type 4 RTA — hyperkalaemic RTA (hyperaldosteronism)
Type 4 RTA is caused by aldosterone deficiency or resistance — the most common type of RTA in clinical practice, occurring in diabetic nephropathy, CKD, and patients on ACE inhibitors, ARBs, or potassium-sparing diuretics. Aldosterone stimulates both hydrogen and potassium secretion in the collecting duct. Without aldosterone activity, both H+ and K+ accumulate — causing metabolic acidosis with hyperkalaemia (the opposite of the hypokalaemia seen in Type 1 and 2 RTA). Type 4 RTA is the most common acid-base disorder in patients with CKD — the reduced renal mass reduces aldosterone-responsive tubular mass. It does not cause kidney stones (acidic urine in type 4 RTA does not favour calcium phosphate stone formation). Treatment focuses on the underlying cause, dietary potassium restriction, and mineralocorticoid replacement (fludrocortisone) in selected patients.
Diagnosis at KIMS
Arterial blood gas (ABG) or venous blood gas
Identifies metabolic acidosis — low pH, low bicarbonate, normal pCO2 (no respiratory compensation if chronic). The first-line confirmation that an acid-base disorder is present and is metabolic rather than respiratory in origin.
Serum electrolytes — sodium, potassium, chloride, bicarbonate
Used for anion gap calculation, identification of hypokalaemia (Type 1 and 2) vs hyperkalaemia (Type 4), and confirmation of low bicarbonate in all types. The potassium pattern is one of the most useful early clues to the RTA type.
Urine pH (spot and timed)
Above 5.3 despite acidaemia = Type 1 RTA — the kidney cannot acidify the urine even when the body is acidotic. May be acidic in Type 2 when serum bicarbonate is very low and the proximal tubule's reduced reabsorption capacity is matched to the available filtered bicarbonate.
Urine anion gap (UAG = Na + K - Cl)
Positive UAG in Type 1 RTA (failure to excrete NH4+ which would carry Cl-). Negative UAG in diarrhoea (which also causes normal anion gap acidosis but through gut HCO3 loss) — distinguishing these two causes is a key application of UAG.
Urine calcium, oxalate, citrate (24-hour)
Hypercalciuria and hypocitraturea in Type 1 RTA — the stone-forming metabolic profile. These measurements are part of the standard KIMS metabolic stone clinic workup for recurrent stone formers.
Serum aldosterone and renin
Low aldosterone with high renin = adrenal insufficiency. Low aldosterone with low renin = hyporeninism (diabetic nephropathy Type 4 RTA) — the most common Type 4 pattern.
Ammonium chloride loading test
Confirms Type 1 RTA — inability to lower urine pH below 5.3 after acidifying challenge. Performed under medical supervision when the diagnosis is uncertain and a definitive confirmation of distal RTA is required.
Renal ultrasound and CT KUB
Nephrocalcinosis (calcium phosphate deposition in medullary pyramids — pathognomonic of distal RTA Type 1) and kidney stones. Imaging is used both to establish the diagnosis and to identify stones that require urological management alongside the metabolic correction.
Treatment — matched to the RTA type
Type 1 RTA — potassium citrate
Potassium citrate treats both the metabolic acidosis and the hypokalaemia (by providing citrate to raise urine citrate and alkali to correct acidosis) AND raises urine pH (potassium citrate alkalinises the urine) AND increases urinary citrate (the key stone inhibitor that is depleted in Type 1 RTA). A single treatment addressing three of the four metabolic abnormalities that cause stones. Dose: typically 60 to 100 mEq/day of citrate in divided doses. Sodium bicarbonate can alternatively be used but does not provide the citrate benefit. Bone disease improves with correction of the acidosis.
Type 2 RTA — high-dose bicarbonate
High-dose bicarbonate supplementation (10 to 15 mEq/kg/day) — but the treatment of the underlying cause (stopping the offending drug, treating myeloma or Wilson's disease) is more important. Type 2 RTA requires substantially more alkali than Type 1 because the leaking proximal tubule wastes bicarbonate at higher rates.
Type 4 RTA — treat the underlying cause
Treat the underlying cause (optimise glycaemic control in diabetic nephropathy, reduce CKD progression). Dietary potassium restriction · Fludrocortisone for confirmed aldosterone deficiency · Loop diuretics for volume expansion-related hyperkalaemia · Review and adjust ACE inhibitors and potassium-sparing diuretics.
Type 1 RTA with recurrent calcium phosphate or mixed stones is one of the most satisfying diagnoses in the KIMS metabolic stone clinic — because it is completely treatable with potassium citrate, and treatment stops stone recurrence almost completely. A patient who has had 5 or 6 stone procedures over 10 years may simply need the correct metabolic diagnosis and a daily potassium citrate tablet.
Book a Metabolic Stone Clinic and RTA Assessment at KIMS
Frequently Asked Questions — Renal Tubular Acidosis
RTA should be suspected when: you have recurrent kidney stones (particularly calcium phosphate stones), nephrocalcinosis on imaging, unexplained metabolic acidosis with normal kidney function, hypokalaemia without obvious cause, or bone pain and osteomalacia without vitamin D deficiency. The diagnosis requires blood tests (serum bicarbonate, potassium, anion gap) and urine tests (urine pH, urine anion gap, 24-hour urine calcium and citrate). At KIMS, the metabolic stone clinic performs these investigations systematically in all patients with recurrent stones or unexplained metabolic acidosis. A 24-hour urine collection with a urine pH above 5.5 in a patient with metabolic acidosis (low serum bicarbonate) is strongly suggestive of Type 1 distal RTA.
Yes — Type 1 (distal) RTA is one of the most important metabolic causes of recurrent kidney stones, particularly calcium phosphate stones and mixed calcium oxalate-phosphate stones. The stone-forming metabolic profile in Type 1 RTA has four components: persistently alkaline urine (calcium phosphate precipitates in alkaline urine), hypercalciuria (chronic acidosis mobilises calcium from bone), hypocitraturea (citrate is reabsorbed to buffer the acidosis, depleting urine citrate — the primary natural stone inhibitor), and sometimes hypercalcaemia (from bone demineralisation). Potassium citrate treatment corrects all four components simultaneously, preventing further stone formation.
The anion gap is a calculated value — serum sodium minus (serum chloride plus serum bicarbonate) — that represents unmeasured anions in the blood. Normal anion gap is 8 to 12 mEq/L. A normal anion gap metabolic acidosis (where the anion gap is normal but bicarbonate is low, and chloride is correspondingly elevated — hyperchloraemic acidosis) is the pattern seen in RTA and in gastrointestinal bicarbonate loss (diarrhoea). A raised anion gap metabolic acidosis (where unmeasured anions such as lactate, ketones, or uraemic toxins are responsible for the acidosis) is seen in lactic acidosis, diabetic ketoacidosis, and advanced kidney failure. The distinction is important because the causes and treatments are completely different.
Some forms are inherited. Type 1 distal RTA can be caused by autosomal dominant mutations (in the AE1 bicarbonate transporter) or autosomal recessive mutations (in the B1 or A4 subunit of the vacuolar H-ATPase pump) — the recessive forms are more severe and are often associated with sensorineural hearing loss (from defective proton pump in the inner ear). Type 2 proximal RTA is associated with hereditary conditions including cystinosis, Wilson's disease, and Lowe syndrome. Type 4 RTA is not inherited but occurs as a complication of acquired conditions (diabetic nephropathy, CKD, medications). Genetic testing for primary RTA is available at KIMS through specialist referral.
Yes — potassium citrate is both safe and beneficial for long-term use in Type 1 RTA. It provides the alkali needed to correct metabolic acidosis, the potassium to replace the obligatory urinary losses, and the citrate to increase urinary citrate and inhibit stone formation. Common formulations include immediate-release tablets (taken with meals to reduce GI side effects) and slow-release formulations (Urocit-K). Side effects are mild — gastrointestinal discomfort with immediate-release formulations in some patients. Potassium citrate is contraindicated in patients with significant renal impairment (eGFR below 30) where potassium accumulation risks hyperkalaemia.
Nephrocalcinosis is the deposition of calcium salts (primarily calcium phosphate) within the kidney parenchyma — visible on renal ultrasound as echogenic (bright white) areas in the medullary pyramids, or on CT as medullary calcifications. The most common causes of medullary nephrocalcinosis are Type 1 distal RTA, primary hyperparathyroidism, and medullary sponge kidney. Not all nephrocalcinosis indicates RTA — hyperparathyroidism, vitamin D toxicity, and sarcoidosis also cause nephrocalcinosis. However, nephrocalcinosis in a patient with normal parathyroid hormone, normal vitamin D, and metabolic acidosis is strongly suggestive of Type 1 RTA. The KIMS metabolic stone clinic evaluates nephrocalcinosis with the full workup.
Yes — Type 1 and Type 2 RTA in children cause failure to thrive and growth retardation from the combination of chronic metabolic acidosis (which diverts amino acids away from protein synthesis toward acid buffering) and metabolic bone disease (rickets in children, osteomalacia in adults). Early diagnosis and treatment with potassium citrate or sodium bicarbonate corrects the acidosis and allows catch-up growth in children if treatment is started before the growth plates close. Children with unexplained poor growth, recurrent vomiting, or developmental delay should have blood pH and electrolytes checked to exclude RTA.
KIMS Secunderabad — Dr. E. Ravi (Senior Consultant Nephrologist), metabolic stone clinic with 24-hour urine collection (calcium, oxalate, citrate, pH, sodium), urine anion gap, ammonium chloride loading test for Type 1 RTA confirmation, NABL-accredited laboratory, potassium citrate and sodium bicarbonate treatment protocols. NABH and NABL accredited. Call 040-4488-5000.